CoChat
Sign Up
Cited by 977Cytokine Signaling Pathways and InteractionsT-cell and B-cell ImmunologyImmune Response and Inflammation

Biology of interleukin-10

Sabat, Robert, Grütz, Gerald, Warszawska, Katarzyna, Kirsch, Stefan, Witte, Ellen, Wolk, Kerstin, Geginat, Jens·2010·Cytokine & Growth Factor Reviews
DOI 10.1016/j.cytogfr.2010.09.002
Open this paper in CoChat — free account

Abstract

Interleukin (IL)-10 is the most important cytokine with anti-inflammatory properties besides TGF-β and IL-35. It is produced by activated immune cells, in particular monocytes/macrophages and T cell subsets including Tr1, Treg, and Th1 cells. IL-10 acts through a transmembrane receptor complex, which is composed of IL-10R1 and IL-10R2, and regulates the functions of many different immune cells. In monocytes/macrophages, IL-10 diminishes the production of inflammatory mediators and inhibits antigen presentation, although it enhances their uptake of antigens. Additionally, IL-10 plays an important role in the biology of B cells and T cells. The special physiological relevance of this cytokine lies in the prevention and limitation of over-whelming specific and unspecific immune reactions and, in consequence, of tissue damage. At the same time, IL-10 strengthens the "scavenger"-function and contributes to induced tolerance. This review provides an overview about the cellular sources, molecular mechanisms, effects, and biological role of IL-10.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cytogfr.2010.09.002

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 251

  1. [1]1. Fiorentino D.F., Bond M.W., Mosmann T.R., Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170, 2081-2095.
  2. [2]2. Kim J.M., Brannan C.I., Copeland N.G., Jenkins N.A., Khan T.A., Moore K.W., Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 1992, 148, 3618-3623.
  3. [3]3. Josephson K., Logsdon N.J., Walter M.R., Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 2001, 15, 35-46.
  4. [4]4. Walter M.R., Nagabhushan T.L., Crystal structure of interleukin 10 reveals an interferon gamma-like fold. Biochemistry 1995, 34, 12118-12125.
  5. [5]5. Zdanov A., Schalk-Hihi C., Gustchina A., Tsang M., Weatherbee J., Wlodawer A., Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 1995, 3, 591-601.
  6. [7]7. Savan R., Ravichandran S., Collins J.R., Sakai M., Young H.A., Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev 2009, 20, 115-124.
  7. [10]10. Biochemistry 1993, 32, 8807-8815.
  8. [11]11. Liu Y., de Waal Malefyt R., Briere F. et al. , The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 1997, 158, 604-613.
  9. [12]12. Volk H., Asadullah K., Gallagher G., Sabat R., Grutz G., IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol 2001, 22, 414-417.
  10. [13]13. Sabat R., Wallace E., Endesfelder S., Wolk K., IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007, 11, 601-612.
  11. [14]14. Wolk K., Sabat R., Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17, 367-380.
  12. [15]15. Wolk K., Kunz S., Asadullah K., Sabat R., Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002, 168, 5397-5402.
  13. [16]16. Murai M., Turovskaya O., Kim G. et al. , Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009, 10, 1178-1184.
  14. [17]17. Roers A., Siewe L., Strittmatter E. et al. , T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 2004, 200, 1289-1297.
  15. [18]18. Seki S., Osada S., Ono S. et al. , Role of liver NK cells and peritoneal macrophages in gamma interferon and interleukin-10 production in experimental bacterial peritonitis in mice. Infect Immun 1998, 66, 5286-5294.
  16. [19]19. Siewe L., Bollati-Fogolin M., Wickenhauser C., Krieg T., Muller W., Roers A., Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur J Immunol 2006, 36, 3248-3255.
  17. [20]20. Blanco P., Palucka A.K., Pascual V., Banchereau J., Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008, 19, 4152.
  18. [21]21. Chomarat P., Rissoan M.C., Banchereau J., Miossec P., Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med 1993, 177, 523-527.
  19. [22]22. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M., B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3, 944-950.
  20. [23]23. Grant L.R., Yao Z.J., Hedrich C.M. et al. , Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun 2008, 9, 316-327.
  21. [24]24. Mehrotra P.T., Donnelly R.P., Wong S. et al. , Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998, 160, 2637-2644.
  22. [25]25. Rhodes K.A., Andrew E.M., Newton D.J., Tramonti D., Carding S.R., A subset of IL-10producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury. Eur J Immunol 2008, 38, 2274-2283.
  23. [26]26. Speiran K., Bailey D.P., Fernando J. et al. , Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukoc Biol 2009, 85, 826-836.
  24. [27]27. Yanaba K., Bouaziz J.D., Matsushita T., Tsubata T., Tedder T.F., The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009, 182, 7459-7472.
  25. [28]28. Zhang X., Majlessi L., Deriaud E., Leclerc C., Lo-Man R., Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009, 31, 761-771.
  26. [29]29. Couper K.N., Blount D.G., Riley E.M., IL-10: the master regulator of immunity to infection. J Immunol 2008, 180, 5771-5777.
  27. [30]30. Banerjee A., Gugasyan R., McMahon M., Gerondakis S., Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A 2006, 103, 3274-3279.
  28. [31]31. Hacker H., Redecke V., Blagoev B. et al. , Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006, 439, 204-207.
  29. [32]32. Meisel C., Vogt K., Platzer C., Randow F., Liebenthal C., Volk H.D., Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 1996, 26, 1580-1586.
  30. [33]33. Platzer C., Meisel C., Vogt K., Platzer M., Volk H.D., Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 1995, 7, 517-523.
  31. [34]34. Suberville S., Bellocq A., Fouqueray B. et al. , Regulation of interleukin-10 production by beta-adrenergic agonists. Eur J Immunol 1996, 26, 2601-2605.
  32. [35]35. Chung E.Y., Liu J., Homma Y. et al. , Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 2007, 27, 952-964.
  33. [36]36. Sharma A., Kumar M., Aich J. et al. , Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A 2009, 106, 5761-5766.
  34. [37]37. Saraiva M., Christensen J.R., Veldhoen M., Murphy T.L., Murphy K.M., O'Garra A., 19. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009, 31, 209-219.
  35. [38]38. Calado D.P., Paixao T., Holmberg D., Haury M., Stochastic monoallelic expression of IL10 in T cells. J Immunol 2006, 177, 5358-5364.
  36. [39]39. Ahyi A.N., Chang H.C., Dent A.L., Nutt S.L., Kaplan M.H., IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J Immunol 2009, 183, 1598-1606.
  37. [40]40. Anderson C.F., Oukka M., Kuchroo V.J., Sacks D., CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007, 204, 285-297.
  38. [41]41. Del Prete G., De Carli M., Almerigogna F., Giudizi M.G., Biagiotti R., Romagnani S., Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993, 150, 353-360.
  39. [42]42. Fitzgerald D.C., Zhang G.X., El-Behi M. et al. , Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007, 8, 1372-1379.
  40. [43]43. Jankovic D., Kullberg M.C., Feng C.G. et al. , Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007, 204, 273-283.
  41. [44]44. Garcia C.A., Wang H., Benakanakere M.R., Barrett E., Kinane D.F., Martin M., c-jun controls the ability of IL-12 to induce IL-10 production from human memory CD4+ T cells. J Immunol 2009, 183, 4475-4482.
  42. [46]46. Stumhofer J.S., Silver J.S., Laurence A. et al. , Interleukins 27 and 6 induce STAT3mediated T cell production of interleukin 10. Nat Immunol 2007, 8, 1363-1371.
  43. [47]47. Groux H., O'Garra A., Bigler M. et al. , A CD4+ T-cell subset inhibits antigen-specific Tcell responses and prevents colitis. Nature 1997, 389, 737-742.
  44. [48]48. Batten M., Kljavin N.M., Li J., Walter M.J., de Sauvage F.J., Ghilardi N., Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol 2008, 180, 2752-2756.
  45. [49]49. Murugaiyan G., Mittal A., Lopez-Diego R., Maier L.M., Anderson D.E., Weiner H.L., IL27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 2009, 183, 2435-2443.
  46. [50]50. Pot C., Jin H., Awasthi A. et al. , Cutting edge: IL-27 induces the transcription factor cMaf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 2009, 183, 797-801.
  47. [53]53. Monteleone G., Pallone F., Macdonald T.T., Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009, 20, 185-191.
  48. [54]54. Spolski R., Kim H.P., Zhu W., Levy D.E., Leonard W.J., IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009, 182, 2859-2867.
  49. [55]55. Xu J., Yang Y., Qiu G. et al. , c-Maf regulates IL-10 expression during Th17 polarization. J Immunol 2009, 182, 6226-6236.
  50. [56]56. Gabrysova L., Nicolson K.S., Streeter H.B. et al. , Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009, 206, 1755-1767.
  51. [57]57. Haringer B., Lozza L., Steckel B., Geginat J., Identification and characterization of IL10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med 2009, 206, 1009-1017.
  52. [58]58. Maynard C.L., Harrington L.E., Janowski K.M. et al. , Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol 2007, 8, 931-941.
  53. [59]59. Denning T.L., Wang Y.C., Patel S.R., Williams I.R., Pulendran B., Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007, 8, 1086-1094.
  54. [60]60. Littman D.R., Rudensky A.Y., Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140, 845-858.
  55. [61]61. Maynard C.L., Hatton R.D., Helms W.S., Oliver J.R., Stephensen C.B., Weaver C.T., Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells. J Exp Med 2009, 206, 343-357.
  56. [62]62. Brandenburg S., Takahashi T., de la Rosa M. et al. , IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 2008, 38, 1643-1653.
  57. [63]63. Tsuji-Takayama K., Suzuki M., Yamamoto M. et al. , The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol 2008, 181, 3897-3905.
  58. [64]64. McLachlan J.B., Catron D.M., Moon J.J., Jenkins M.K., Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 2009, 30, 277-288.
  59. [65]65. Zhang N., Schroppel B., Lal G. et al. , Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009, 30, 458-469.
  60. [66]66. Vanden Eijnden S., Goriely S., De Wit D., Willems F., Goldman M., IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005, 35, 469-475.
  61. [67]67. Wolk K., Witte E., Witte K., Warszawska K., Sabat R., Biology of interleukin-22. Semin Immunopathol 2010, 32, 17-31.
  62. [68]68. Diveu C., McGeachy M.J., Boniface K. et al. , IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 2009, 182, 5748-5756.
  63. [70]70. Frasca L., Nasso M., Spensieri F. et al. , IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol 2008, 180, 1471-1481.
  64. [71]71. McGeachy M.J., Bak-Jensen K.S., Chen Y. et al. , TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8, 1390-1397.
  65. [73]73. Kotenko S.V., The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002, 13, 223-240.
  66. [75]75. Liu Y., Wei S.H., Ho A.S., de Waal Malefyt R., Moore K.W., Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994, 152, 1821-1829.
  67. [76]76. Taniyama T., Takai S., Miyazaki E. et al. , The human interleukin-10 receptor gene maps to chromosome 11q23.3. Hum Genet 1995, 95, 99-101.
  68. [77]77. Gasche C., Grundtner P., Zwirn P. et al. , Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol 2003, 170, 5578-5582.
  69. [78]78. Hofer H., Neufeld J.B., Oesterreicher C. et al. , Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes Immun 2005, 6, 242-247.
  70. [79]79. Kotenko S.V., Krause C.D., Izotova L.S., Pollack B.P., Wu W., Pestka S., Identification and functional characterization of a second chain of the interleukin-10 receptor complex. Embo J 1997, 16, 5894-5903.
  71. [80]80. Reineke U., Schneider-Mergener J., Glaser R.W. et al. , Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J Mol Recognit 1999, 12, 242-248.
  72. [81]81. Wolk K., Witte E., Reineke U. et al. , Is there an interaction between interleukin-10 and interleukin-22? Genes Immun 2005, 6, 8-18.
  73. [82]82. Yoon S.I., Logsdon N.J., Sheikh F., Donnelly R.P., Walter M.R., Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J Biol Chem 2006, 281, 35088-35096.
  74. [83]83. Logsdon N.J., Jones B.C., Josephson K., Cook J., Walter M.R., Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J Interferon Cytokine Res 2002, 22, 1099-1112.
  75. [84]84. Reineke U., Sabat R., Volk H.D., Schneider-Mergener J., Mapping of the interleukin10/interleukin-10 receptor combining site. Protein Sci 1998, 7, 951-960.
  76. [86]86. Carson W.E., Lindemann M.J., Baiocchi R. et al. , The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995, 85, 3577-3585.
  77. [87]87. Jurlander J., Lai C.F., Tan J. et al. , Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997, 89, 4146-4152.
  78. [88]88. Kunz S., Wolk K., Witte E. et al. , Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006, 15, 9911004.
  79. [89]89. Wolk K., Witte K., Witte E. et al. , Maturing dendritic cells are an important source of IL29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008, 83, 1181-1193.
  80. [90]90. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R., IL-22 increases the innate immunity of tissues. Immunity 2004, 21, 241-254.
  81. [91]91. Geginat J., Sallusto F., Lanzavecchia A., Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001, 194, 1711-1719.
  82. [92]92. Seifert M., Gruenberg B.H., Sabat R. et al. , Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol 2003, 12, 137-144.
  83. [95]95. Ding Y., Qin L., Zamarin D. et al. , Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J Immunol 2001, 167, 6884-6892.
  84. [96]96. Wolk K., Haugen H.S., Xu W. et al. , IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009, 87, 523-536.
  85. [97]97. Kotenko S.V., Gallagher G., Baurin V.V. et al. , IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4, 69-77.
  86. [98]98. Sheikh F., Baurin V.V., Lewis-Antes A. et al. , Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol 2004, 172, 2006-2010.
  87. [99]99. Sheppard P., Kindsvogel W., Xu W. et al. , IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4, 63-68.
  88. [100]100. Xie M.H., Aggarwal S., Ho W.H. et al. , Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000, 275, 31335-31339.
  89. [101]101. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J., IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 2008, 19, 383-394.
  90. [102]102. Finbloom D.S., Winestock K.D., IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995, 155, 1079-1090.
  91. [103]103. Weber-Nordt R.M., Riley J.K., Greenlund A.C., Moore K.W., Darnell J.E., Schreiber R.D., Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 1996, 271, 27954-27961.
  92. [104]104. Wehinger J., Gouilleux F., Groner B., Finke J., Mertelsmann R., Weber-Nordt R.M., IL10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996, 394, 365-370.
  93. [106]106. Kretzschmar A.K., Dinger M.C., Henze C., Brocke-Heidrich K., Horn F., Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J 2004, 377, 289-297.
  94. [107]107. Novak U., Ji H., Kanagasundaram V., Simpson R., Paradiso L., STAT3 forms stable homodimers in the presence of divalent cations prior to activation. Biochem Biophys Res Commun 1998, 247, 558-563.
  95. [108]108. Schroder M., Kroeger K.M., Volk H.D., Eidne K.A., Grutz G., Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation? J Leukoc Biol 2004, 75, 792-797.
  96. [109]109. Piessevaux J., Lavens D., Peelman F., Tavernier J., The many faces of the SOCS box. Cytokine Growth Factor Rev 2008, 19, 371-381.
  97. [110]110. Ito S., Ansari P., Sakatsume M. et al. , Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999, 93, 1456-1463.
  98. [111]111. Riley J.K., Takeda K., Akira S., Schreiber R.D., Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999, 274, 16513-16521.
  99. [112]112. Crawley J.B., Williams L.M., Mander T., Brennan F.M., Foxwell B.M., Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J Biol Chem 1996, 271, 16357-16362.
  100. [113]113. Ho A.S., Wei S.H., Mui A.L., Miyajima A., Moore K.W., Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol Cell Biol 1995, 15, 5043-5053.
  101. [114]114. Jung M., Sabat R., Kratzschmar J. et al. , Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 2004, 34, 481-493.
  102. [116]116. Hart P.H., Hunt E.K., Bonder C.S., Watson C.J., Finlay-Jones J.J., Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 1996, 157, 3672-3680.
  103. [117]117. Jenkins J.K., Malyak M., Arend W.P., The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994, 13, 47-54.
  104. [118]118. Joyce D.A., Gibbons D.P., Green P., Steer J.H., Feldmann M., Brennan F.M., Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994, 24, 2699-2705.
  105. [119]119. Kruglov A.A., Kuchmiy A., Grivennikov S.I., Tumanov A.V., Kuprash D.V., Nedospasov S.A., Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 2008, 19, 231-244.
  106. [120]120. Creery W.D., Diaz-Mitoma F., Filion L., Kumar A., Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 1996, 26, 1273-1277.
  107. [121]121. de Waal Malefyt R., Haanen J., Spits H. et al. , Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigenpresenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174, 915-924.
  108. [122]122. Willems F., Marchant A., Delville J.P. et al. , Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994, 24, 1007-1009.
  109. [123]123. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G., Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993, 178, 1041-1048.
  110. [124]124. Billiau A., Matthys P., Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009, 20, 97-113.
  111. [125]125. Schuetze N., Schoeneberger S., Mueller U., Freudenberg M.A., Alber G., Straubinger R.K., IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int Immunol 2005, 17, 649-659.
  112. [126]126. Buchwald U.K., Geerdes-Fenge H.F., Vockler J., Ziege S., Lode H., Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Eur J Med Res 1999, 4, 85-94.
  113. [127]127. Calzada-Wack J.C., Frankenberger M., Ziegler-Heitbrock H.W., Interleukin-10 drives human monocytes to CD16 positive macrophages. J Inflamm 1996, 46, 78-85.
  114. [128]128. Spittler A., Schiller C., Willheim M., Tempfer C., Winkler S., Boltz-Nitulescu G., IL-10 augments CD23 expression on U937 cells and down-regulates IL-4-driven CD23 expression on cultured human blood monocytes: effects of IL-10 and other cytokines on cell phenotype and phagocytosis. Immunology 1995, 85, 311-317.
  115. [129]129. te Velde A.A., de Waal Malefijt R., Huijbens R.J., de Vries J.E., Figdor C.G., IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 1992, 149, 4048-4052.
  116. [130]130. Roilides E., Anastasiou-Katsiardani A., Dimitriadou-Georgiadou A. et al. , Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. J Infect Dis 1998, 178, 1734-1742.
  117. [131]131. Koch N., Jung M., Sabat R. et al. , IL-10 protects monocytes and macrophages from complement-mediated lysis. J Leukoc Biol 2009, 86, 155-166.
  118. [132]132. Vicioso M.A., Garaud J.J., Reglier-Poupet H., Lebeaut A., Gougerot-Pocidalo M.A., Chollet-Martin S., Moderate inhibitory effect of interleukin-10 on human neutrophil and monocyte chemotaxis in vitro. Eur Cytokine Netw 1998, 9, 247-253.
  119. [133]133. Allavena P., Piemonti L., Longoni D. et al. , IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998, 28, 359-369.
  120. [134]134. Schoenbein C., Docke W.D., Wolk K. et al. , Long-term interleukin-10 presence induces the development of a novel, monocyte-derived cell type. Clin Exp Immunol 2008, 151, 306316.
  121. [135]135. Fitzgerald-Bocarsly P., Dai J., Singh S., Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008, 19, 3-19.
  122. [136]136. Duramad O., Fearon K.L., Chan J.H. et al. , IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 2003, 102, 4487-4492.
  123. [137]137. Waibler Z., Anzaghe M., Konur A., Akira S., Muller W., Kalinke U., Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC. Eur J Immunol 2008, 38, 3127-3137.
  124. [138]138. Groux H., Bigler M., de Vries J.E., Roncarolo M.G., Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996, 184, 19-29.
  125. [139]139. Naundorf S., Schroder M., Hoflich C., Suman N., Volk H.D., Grutz G., IL-10 interferes directly with TCR-induced IFN-gamma but not IL-17 production in memory T cells. Eur J 8. Immunol 2009, 39, 1066-1077.
  126. [140]140. Groux H., Bigler M., de Vries J.E., Roncarolo M.G., Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998, 160, 3188-3193.
  127. [141]141. Kemper C., Chan A.C., Green J.M., Brett K.A., Murphy K.M., Atkinson J.P., Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003, 421, 388-392.
  128. [142]142. Baecher-Allan C., Viglietta V., Hafler D.A., Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16, 89-98.
  129. [143]143. Ito T., Hanabuchi S., Wang Y.H. et al. , Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008, 28, 870-880.
  130. [144]144. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A., Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009, 182, 6121-6128.
  131. [146]146. Cassatella M.A., Meda L., Bonora S., Ceska M., Constantin G., Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993, 178, 2207-2211.
  132. [147]147. Kasama T., Strieter R.M., Lukacs N.W., Burdick M.D., Kunkel S.L., Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994, 152, 3559-3569.
  133. [148]148. Niiro H., Otsuka T., Izuhara K. et al. , Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 1997, 89, 1621-1628.
  134. [149]149. Takanaski S., Nonaka R., Xing Z., O'Byrne P., Dolovich J., Jordana M., Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 1994, 180, 711-715.
  135. [150]150. Keel M., Ungethum U., Steckholzer U. et al. , Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997, 90, 3356-3363.
  136. [151]151. Arock M., Zuany-Amorim C., Singer M., Benhamou M., Pretolani M., Interleukin-10 inhibits cytokine generation from mast cells. Eur J Immunol 1996, 26, 166-170.
  137. [152]152. Lin T.J., Befus A.D., Differential regulation of mast cell function by IL-10 and stem cell factor. J Immunol 1997, 159, 4015-4023.
  138. [153]153. Kennedy Norton S., Barnstein B., Brenzovich J. et al. , IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 2008, 180, 2848-2854.
  139. [154]154. Burdin N., Rousset F., Banchereau J., B-cell-derived IL-10: production and function. Methods 1997, 11, 98-111.
  140. [155]155. Go N.F., Castle B.E., Barrett R. et al. , Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990, 172, 1625-1631.
  141. [156]156. Levy Y., Brouet J.C., Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994, 93, 424-428.
  142. [157]157. Rousset F., Peyrol S., Garcia E. et al. , Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int Immunol 1995, 7, 1243-1253.
  143. [158]158. Vieira P., de Waal-Malefyt R., Dang M.N. et al. , Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 1991, 88, 1172-1176.
  144. [159]159. Gruber S.G., Gloria Luciani M., Grundtner P., Zdanov A., Gasche C., Differential signaling of cmvIL-10 through common variants of the IL-10 receptor 1. Eur J Immunol 2008, 38, 3365-3375.
  145. [160]160. Takeda K., Clausen B.E., Kaisho T. et al. , Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10, 39-49.
  146. [161]161. El Kasmi K.C., Holst J., Coffre M. et al. , General nature of the STAT3-activated antiinflammatory response. J Immunol 2006, 177, 7880-7888.
  147. [162]162. Williams L., Bradley L., Smith A., Foxwell B., Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172, 567-576.
  148. [163]163. Minegishi Y., Saito M., Tsuchiya S. et al. , Dominant-negative mutations in the DNAbinding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448, 1058-1062.
  149. [164]164. Woellner C., Gertz E.M., Schaffer A.A. et al. , Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010, 125, 424-432 e428.
  150. [165]165. Rossato M., Cencig S., Gasperini S., Cassatella M.A., Bazzoni F., IL-10 modulates cytokine gene transcription by protein synthesis-independent and dependent mechanisms in lipopolysaccharide-treated neutrophils. Eur J Immunol 2007, 37, 3176-3189.
  151. [166]166. Lang R., Patel D., Morris J.J., Rutschman R.L., Murray P.J., Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002, 169, 2253-2263.
  152. [167]167. Williams L., Jarai G., Smith A., Finan P., IL-10 expression profiling in human monocytes. J Leukoc Biol 2002, 72, 800-809.
  153. [169]169. Schmid J.A., Birbach A., IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 2008, 19, 157-165.
  154. [170]170. Wertz I.E., Dixit V.M., Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev 2008, 19, 313-324.
  155. [171]171. Grutz G., New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005, 77, 3-15.
  156. [172]172. Baetz A., Frey M., Heeg K., Dalpke A.H., Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem 2004, 279, 54708-54715.
  157. [173]173. Gingras S., Parganas E., de Pauw A., Ihle J.N., Murray P.J., Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem 2004, 279, 54702-54707.
  158. [174]174. Nakagawa R., Naka T., Tsutsui H. et al. , SOCS-1 participates in negative regulation of LPS responses. Immunity 2002, 17, 677-687.
  159. [175]175. Croker B.A., Krebs D.L., Zhang J.G. et al. , SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003, 4, 540-545.
  160. [176]176. Lang R., Pauleau A.L., Parganas E. et al. , SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4, 546-550.
  161. [177]177. Yasukawa H., Ohishi M., Mori H. et al. , IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4, 551-556.
  162. [178]178. Hammer M., Mages J., Dietrich H. et al. , Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur J Immunol 2005, 35, 2991-3001.
  163. [179]179. Chi H., Barry S.P., Roth R.J. et al. , Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 2006, 103, 2274-2279.
  164. [181]181. Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., Oravecz T., Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006, 176, 1899-1907.
  165. [183]183. Dagvadorj J., Naiki Y., Tumurkhuu G. et al. , Interleukin-10 inhibits tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. Innate Immun 2008, 14, 109-115.
  166. [184]184. Chang J., Kunkel S.L., Chang C.H., Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc Natl Acad Sci U S A 2009, 106, 18327-18332.
  167. [185]185. McCoy C.E., Sheedy F.J., Qualls J.E. et al. , IL-10 inhibits miR-155 induction by tolllike receptors. J Biol Chem 2010, 285, 20492-20498.
  168. [186]186. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D., Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 2009, 106, 7113-7118.
  169. [187]187. Sly L.M., Rauh M.J., Kalesnikoff J., Song C.H., Krystal G., LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004, 21, 227-239.
  170. [188]188. Murray P.J., The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A 2005, 102, 8686-8691.
  171. [189]189. Driessler F., Venstrom K., Sabat R., Asadullah K., Schottelius A.J., Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004, 135, 64-73.
  172. [190]190. Cao S., Zhang X., Edwards J.P., Mosser D.M., NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006, 281, 26041-26050.
  173. [191]191. Kuwata H., Watanabe Y., Miyoshi H. et al. , IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003, 102, 4123-4129.
  174. [193]193. Weaver B.K., Bohn E., Judd B.A., Gil M.P., Schreiber R.D., ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol 2007, 27, 4603-4616.
  175. [195]195. Muhlbauer M., Chilton P.M., Mitchell T.C., Jobin C., Impaired Bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice. J Biol Chem 2008, 283, 14182-14189.
  176. [196]196. Bogdan C., Paik J., Vodovotz Y., Nathan C., Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem 1992, 267, 23301-23308.
  177. [197]197. Brown C.Y., Lagnado C.A., Vadas M.A., Goodall G.J., Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10. J Biol Chem 1996, 271, 20108-20112.
  178. [198]198. Kishore R., Tebo J.M., Kolosov M., Hamilton T.A., Cutting edge: clustered AU-rich elements are the target of IL-10-mediated mRNA destabilization in mouse macrophages. J Immunol 1999, 162, 2457-2461.
  179. [199]199. Kontoyiannis D., Kotlyarov A., Carballo E. et al. , Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. Embo J 2001, 20, 3760-3770.
  180. [200]200. Denys A., Udalova I.A., Smith C. et al. , Evidence for a dual mechanism for IL-10 suppression of TNF-alpha production that does not involve inhibition of p38 mitogenactivated protein kinase or NF-kappa B in primary human macrophages. J Immunol 2002, 168, 4837-4845.
  181. [201]201. Gaestel M., MAPKAP kinases - MKs - two's company, three's a crowd. Nat Rev Mol Cell Biol 2006, 7, 120-130.
  182. [202]202. Rajasingh J., Bord E., Luedemann C. et al. , IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. Faseb J 2006, 20, 2112-2114.
  183. [203]203. Schaljo B., Kratochvill F., Gratz N. et al. , Tristetraprolin is required for full antiinflammatory response of murine macrophages to IL-10. J Immunol 2009, 183, 1197-1206.
  184. [204]204. Krishnamurthy P., Lambers E., Verma S. et al. , Myocardial knockdown of mRNAstabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. Faseb J 2010, 24, 2484-2494.
  185. [205]205. Koppelman B., Neefjes J.J., de Vries J.E., de Waal Malefyt R., Interleukin-10 downregulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997, 7, 861-871.
  186. [206]206. Thibodeau J., Bourgeois-Daigneault M.C., Huppe G. et al. , Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol 2008, 38, 1225-1230.
  187. [207]207. Schroder M., Meisel C., Buhl K. et al. , Different modes of IL-10 and TGF-beta to inhibit cytokine-dependent IFN-gamma production: consequences for reversal of lipopolysaccharide desensitization. J Immunol 2003, 170, 5260-5267.
  188. [208]208. de Waal Malefyt R., Yssel H., de Vries J.E., Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993, 150, 4754-4765.
  189. [209]209. Joss A., Akdis M., Faith A., Blaser K., Akdis C.A., IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000, 30, 1683-1690.
  190. [210]210. Grondal G., Kristjansdottir H., Gunnlaugsdottir B. et al. , Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 1999, 42, 1649-1654.
  191. [211]211. Stewart J.P., Behm F.G., Arrand J.R., Rooney C.M., Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 1994, 200, 724-732.
  192. [212]212. Yue F.Y., Dummer R., Geertsen R. et al. , Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997, 71, 630-637.
  193. [213]213. Salhi A., Rodrigues V., Jr., Santoro F. et al. , Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 2008, 180, 6139-6148.
  194. [214]214. Berres M.L., Schnyder B., Yagmur E. et al. , Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int 2009, 29, 536-543.
  195. [215]215. Docke W.D., Randow F., Syrbe U. et al. , Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3, 678-681.
  196. [216]216. Steinhauser M.L., Hogaboam C.M., Kunkel S.L., Lukacs N.W., Strieter R.M., Standiford T.J., IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999, 162, 392-399.
  197. [217]217. Woiciechowsky C., Asadullah K., Nestler D. et al. , Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998, 4, 808-813.
  198. [218]218. Wolk K., Docke W.D., von Baehr V., Volk H.D., Sabat R., Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000, 96, 218-223.
  199. [219]219. Wolk K., Hoflich C., Zuckermann-Becker H., Docke W.D., Volk H.D., Sabat R., Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit Care Med 2007, 35, 458-467.
  200. [220]220. Chiu B.C., Stolberg V.R., Chensue S.W., Mononuclear phagocyte-derived IL-10 suppresses the innate IL-12/IFN-gamma axis in lung-challenged aged mice. J Immunol 2008, 181, 3156-3166.

200 of 251 shown

Cited by

Sorted by citations

Authors
Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J.
Affiliations
  • Stiftung Charité (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Istituto Nazionale Genetica Molecolare (IT)
Corresponding author
Sabat, Robert
ORCID
Venue
Cytokine & Growth Factor Reviews
Publisher
Elsevier BV
Published
2010-10
Volume
21
Issue
5
Pages
331-344
ISSN
1359-6101 (ISSN-L)
DOI
10.1016/j.cytogfr.2010.09.002
OpenAlex
W2069305891
Cited by
977
References
11
Citations by year
2026: 36 · 2025: 46 · 2024: 77 · 2023: 61 · 2022: 68 · 2021: 66 · 2020: 52 · 2019: 64 · 2018: 56 · 2017: 65 · 2016: 67 · 2015: 64 · 2014: 73 · 2013: 67 · 2012: 79
FWCI
6.35
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Cytokine & Growth Factor Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Helmholtz-Zentrum Geesthacht Zentrum für Materialforschung und kustenforschung (The Helmholtz Center Geesthacht) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
IL-10, anti-inflammatory cytokines, IL-10R2, monocytes/macrophages, T cell subsets, regulatory T cells, Th1 cells, antigen presentation, B cells, induced tolerance, tissue damage prevention, cytokine signaling
MeSH terms
Animals, B-Lymphocytes, Humans, Macrophages, Monocytes, T-Lymphocyte Subsets, Interleukin-10

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review